BSE: 512036
SKYBIOTECH HEALTHCARE LIMITED
Rebranded from Kapil Cotex Limited to Skybiotech Healthcare Limited effective 7 November 2025, with its Corporate Identification Number reclassified from L17100 (textiles) to L21001 (pharmaceuticals and healthcare), reflecting a stated pivot into healthcare. On a standalone basis, the original textile business is effectively dormant: standalone revenue from operations was just Rs 1.54 lakh in Q2 FY26 and zero in Q3 FY26. The actual activity sits in subsidiary Skybiotech Life Sciences Pvt Ltd, which contributed Rs 733.69 lakh of income but a loss of Rs 105.72 lakh in FY26. Consolidated FY26 revenue from operations was Rs 709.78 lakh (up 0.65% YoY), with a consolidated net loss of Rs 111.68 lakh, narrower than the Rs 236.89 lakh loss in FY25. Quarterly trends are choppy — consolidated Q2 FY26 revenue of Rs 191.65 lakh collapsed to Rs 96.27 lakh in Q3 FY26. Materials make up 43.6% of revenue, employees 24.8%, and other operating expenses 40.8%. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Healthcare / life sciences (via subsidiary Skybiotech Life Sciences Pvt Ltd), Legacy textiles (standalone). Small BSE-listed shell that has rebranded from textiles to healthcare; revenue is concentrated in a single loss-making subsidiary and has been choppy across recent quarters.
Exhibit 1: Financial summary, FY25–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 7 | 7 |
| EBITDA (ex other income) | (2) | (1) |
| margin % | (32.0) | (20.8) |
| Owners' profit | 0 | (1) |
| EPS, as reported (₹) | 14.19 | (6.70) |
| ROE % · ROCE % | (22.5) · (13.8) | (12.1) · (9.4) |
| Debt / equity (x) | 0.68 | 0.91 |
| Cash from operations | (1) | (2) |
| Capex | 0 | (0) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 1 | 2 | 2 | 1 | 2 |
| Profit before tax | (0) | (0) | (0) | (1) | (0) | (0) | (0) | (1) |
| Net profit | (0) | (0) | (0) | (1) | (0) | (0) | (0) | (0) |
| EPS (₹) | 0.25 | 5.46 | (3.06) | 13.68 | 0.25 | (1.29) | (1.29) | (2.96) |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| KPR MILL LTD. | 37,325 | 40.9 | 6.55 | 27.0 | 15.2 | 19.3 | 13.5 | 21.2 |
| WELSPUN LIVING LIMITED | 20,367 | 74.1 | 4.09 | 26.1 | 4.3 | 4.0 | 5.1 | 12.7 |
| VARDHMAN TEXTILES LIMITED | 14,669 | 17.0 | 1.39 | 11.3 | 7.1 | 7.4 | 10.0 | 20.4 |
| TRIDENT LIMITED | 10,870 | 27.4 | 2.28 | 13.4 | 7.9 | 8.6 | 8.1 | 17.7 |
| INDO COUNT INDUSTRIES LTD | 8,471 | 56.1 | 3.60 | 20.4 | 5.4 | 5.4 | 10.5 | 13.3 |
| GARWARE TECH FIBRES LTD | 7,310 | 35.3 | 5.40 | 22.9 | 14.7 | 18.7 | 8.1 | 20.5 |
| FILATEX INDIA LTD | 4,207 | 22.0 | 2.80 | 11.5 | 12.2 | 13.8 | — | 7.6 |
| SANATHAN TEXTILES LIMITED | 4,178 | 68.8 | 2.23 | 18.6 | 4.1 | 3.5 | — | 8.4 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 2.4 | 1.1 | 144 of 185 | 22% |
| ROCE | (9.5) | 4.3 | 197 of 215 | 8% |
| ROE | (12.1) | 4.7 | 178 of 188 | 5% |
| Debt / Equity | 0.9 | 0.4 | 140 of 188 | 26% |
| EBITDA margin | (39.7) | 9.8 | 193 of 198 | 3% |
| Revenue growth | 79.7 | 6.9 | 25 of 192 | 87% |
| Profit growth | 72.0 | 20.0 | 69 of 203 | 66% |
| Market cap | 22 | 61 | 165 of 223 | 26% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 16 Oct 2026 · Compliance certificate for share dematerialization for Sep 2026 quarter | compliance | minimal | — | — |
| 1 Oct 2026 · 43rd AGM: All 4 resolutions passed with over 99.99 percent majority | compliance | minimal | — | — |
| 1 Oct 2026 · Trading Window closed for Q2 FY27 results declaration | compliance | minimal | — | — |
| 30 Sept 2026 · 43rd AGM proceedings; 4 ordinary resolutions passed; name change compliance ratified | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Outcome of 43rd AGM of SKYBIOTECH HEALTHCARE LIMITED held on 30 Sep 2026 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Notice of 43rd AGM on September 30, 2026 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · FY26 Annual Report filed; pharma pivot, losses persist | general | low | — | — |
| 11 Aug 2026 · Board Meeting on 14 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 19 Jul 2026 · Compliance Certificate under Reg 74(5) for Q1 FY27 | compliance | minimal | — | — |
| 27 Jun 2026 · Trading Window Closure from 1 July 2026 for Q1 FY27 Results | compliance | minimal | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.